Effect of genotypic differences in CYP2C19 status on the cure rates for gastroesophageal reflux disease by lansoplazole

被引：0
|
作者：
Furuta, T [1 ]
Shirai, N [1 ]
Xiao, P [1 ]
Kajimura, M [1 ]
Hanai, H [1 ]
机构：
[1] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 43131, Japan
来源：
GASTROENTEROLOGY | 2001年 / 120卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2203
引用
收藏
页码：A432 / A432
页数：1
相关论文
共 50 条
  • [41] The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
    Kawamura, M
    Ohara, S
    Koike, T
    Iijima, K
    Suzuki, J
    Kayaba, S
    Noguchi, K
    Hamada, S
    Noguchi, M
    Shimosegawa, T
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (07) : 965 - 973
  • [42] CYP2C19 polymorphism affects the treatment effects for reflux esophagitis with lansoprazole
    Kawamura, M
    Ohara, S
    Sekine, H
    Koike, T
    Abe, Y
    Shimosegawa, T
    Yoshida, M
    Kitagawa, Y
    GASTROENTEROLOGY, 2002, 122 (04) : A195 - A195
  • [43] The therapeutic effect of lansoprazole on erosive reflux esophagitis in maintenance treatment was influenced by CYP2C19 polymorphisin
    Kawamura, M
    Ohara, S
    Sekine, H
    Koike, T
    Kitagawa, Y
    Yoshida, M
    Abe, Y
    Shimosegawa, T
    GASTROENTEROLOGY, 2003, 124 (04) : A227 - A227
  • [44] Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis
    Ohkusa, T
    Maekawa, T
    Arakawa, T
    Nakajima, M
    Fujimoto, K
    Hoshino, E
    Mitachi, Y
    Hamada, S
    Mine, T
    Kawahara, Y
    Nagai, T
    Aoyama, N
    Yoshida, N
    Tadokoro, K
    Chida, N
    Konda, Y
    Seno, H
    Shimatani, T
    Inoue, M
    Sato, N
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (11) : 1331 - 1339
  • [45] The effect of CYP2C19 and CYP2C9 polymorphism on the pharmacodynamics of clopidogrel
    Jiang, Juanjuan
    Tian, Lei
    Han, Lulu
    Yan, Yan
    Huang, Yiling
    Liu, Hong
    Xie, Shuang
    Li, Yishi
    CARDIOLOGY, 2011, 120 : 30 - 31
  • [46] Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
    Daniele Jones
    Shana Persad-Ramdeensingh
    Sheherazade Crystal Abrahim
    Naveen Seecheran
    Rajini Rani Haraksingh
    Cardiology and Therapy, 2024, 13 : 191 - 203
  • [47] Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
    Jones, Daniele
    Persad-Ramdeensingh, Shana
    Abrahim, Sheherazade Crystal
    Seecheran, Naveen
    Haraksingh, Rajini Rani
    CARDIOLOGY AND THERAPY, 2024, 13 (01) : 191 - 203
  • [48] Individual and ethnic differences in CYP2C19 activity in Chinese populations
    Shu, Y
    Zhou, HH
    ACTA PHARMACOLOGICA SINICA, 2000, 21 (03): : 193 - 199
  • [49] Metabolism disposition of lansoprazole in relation to the CYP2C19 phenotype status
    fu, liangqing
    wu, dezheng
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 224 - 224
  • [50] CYP2C19 genotype is a useful marker of optimal dose of a proton pump inhibitor in the maintenance therapy of symptomatic gastroesophageal reflux diseases
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Kodaira, Chise
    Nishino, Masafumi
    Yamade, Mihoko
    Ikuma, Mutsuhiro
    Kimura, Michio
    Hishida, Akira
    Ishizaki, Takashi
    GASTROENTEROLOGY, 2008, 134 (04) : A172 - A173
12345